Partner Nate Lacktman appeared on a segment of NPR’s All things Considered, “Phone Scammers And ‘Teledoctors’ Charged With Preying On Seniors In Fraud Case,” about alleged Medicare scammers using telemedicine and unscrupulous health providers to prescribe unneeded medical equipment to distant patients.
Lacktman, chair of the firm’s national Telemedicine & Digital Health Industry Team, was quick to point out that the telemedicine industry does not regard the fraudsters involved in such schemes as legitimate businesses. “These are actually really sketchy online marketing companies participating in these schemes, who are billing themselves as telemedicine,” he said. “But in fact, they are companies we’ve never heard of.”
Lacktman, chair of the firm’s national Telemedicine & Digital Health Industry Team, was quick to point out that the telemedicine industry does not regard the fraudsters involved in such schemes as legitimate businesses. “These are actually really sketchy online marketing companies participating in these schemes, who are billing themselves as telemedicine,” he said. “But in fact, they are companies we’ve never heard of.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”